KR101282335B1 - 레몬밤 추출물을 유효성분으로 함유하는 피부미백 개선용 조성물 - Google Patents
레몬밤 추출물을 유효성분으로 함유하는 피부미백 개선용 조성물 Download PDFInfo
- Publication number
- KR101282335B1 KR101282335B1 KR1020100008531A KR20100008531A KR101282335B1 KR 101282335 B1 KR101282335 B1 KR 101282335B1 KR 1020100008531 A KR1020100008531 A KR 1020100008531A KR 20100008531 A KR20100008531 A KR 20100008531A KR 101282335 B1 KR101282335 B1 KR 101282335B1
- Authority
- KR
- South Korea
- Prior art keywords
- lemon balm
- extract
- balm extract
- composition
- skin whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 244000062730 Melissa officinalis Species 0.000 title claims abstract description 103
- 235000010654 Melissa officinalis Nutrition 0.000 title claims abstract description 100
- 239000000284 extract Substances 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000000694 effects Effects 0.000 title abstract description 28
- 230000002087 whitening effect Effects 0.000 claims abstract description 25
- 230000008099 melanin synthesis Effects 0.000 claims abstract description 17
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 abstract description 33
- 102000003425 Tyrosinase Human genes 0.000 abstract description 31
- 108090000623 proteins and genes Proteins 0.000 abstract description 29
- 210000003491 skin Anatomy 0.000 abstract description 29
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 28
- 210000002752 melanocyte Anatomy 0.000 abstract description 23
- 230000014509 gene expression Effects 0.000 abstract description 19
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 229930003935 flavonoid Natural products 0.000 abstract description 16
- 150000002215 flavonoids Chemical class 0.000 abstract description 16
- 235000017173 flavonoids Nutrition 0.000 abstract description 16
- 230000002829 reductive effect Effects 0.000 abstract description 12
- 235000001674 Agaricus brunnescens Nutrition 0.000 abstract description 7
- 239000000049 pigment Substances 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000001678 irradiating effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000036564 melanin content Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000036559 skin health Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 3
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000012261 overproduction Methods 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150006914 TRP1 gene Proteins 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- -1 lignen Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명에 따르면, 상기 레몬밤에 자외선을 조사시켜 플라보노이드의 함량이 증가된 레몬밤 추출물을 제조할 수 있다. 본 발명의 레몬밤 추출물은 일반 레몬밤 추출물에 비해 플라보노이드의 함량이 증가하여 항산화 효능이 높아졌으며, 버섯 티로시나제의 활성을 억제함을 확인하였다. 또한 마우스 멜라닌 세포의 멜라닌 합성량을 감소시킬 뿐만 아니라 멜라닌 색소 형성에 관여하는 유전자 및 단백질의 발현을 동시에 억제하였다. 따라서 본 발명의 레몬밤 추출물은 피부미백 효과가 탁월하며, 이를 이용한 피부미백용 화장료 조성물의 활용이 기대된다.
Description
도 2는 레몬밤 추출물의 버섯 티로시나제의 활성평가 결과를 나타낸 것이다.
도 3은 레몬밤 추출물 처리에 따른 마우스 멜라닌 세포의 독성평가 결과를 나타낸 것이다.
도 4는 레몬밤 추출물 처리에 따른 마우스 멜라닌 세포의 티로시나제 활성평가 결과를 나타낸 것이다.
도 5는 레몬밤 추출물 처리에 따른 마우스 멜라닌 세포의 멜라닌 함량 측정 결과를 나타낸 것이다.
도 6은 레몬밤 추출물 처리에 따른 마우스 멜라닌 세포의 멜라닌 합성에 관여하는 유전자들의 전기영동 결과를 나타낸 것이다.
도 7은 증폭된 티로시나제 유전자의 양을 정량한 결과를 나타낸 것이다.
도 8은 증폭된 TRP-1 유전자의 양을 정량한 결과를 나타낸 것이다.
도 9는 증폭된 TRP-2 유전자의 양을 정량한 결과를 나타낸 것이다.
도 10은 레몬밤 추출물 처리에 따른 마우스 멜라닌 세포의 멜라닌 합성에 관여하는 단백질들의 웨스턴 블롯 분석 결과를 나타낸 것이다.
도 11은 발현된 티로시나제 단백질의 양을 정량한 결과를 나타낸 것이다.
도 12는 발현된 TRP-1 단백질의 양을 정량한 결과를 나타낸 것이다.
도 13은 발현된 TRP-2 단백질의 양을 정량한 결과를 나타낸 것이다.
Claims (6)
- UV-B 자외선을 7 Wm-2s-2로 10~30일간 조사한 레몬밤 추출물을 유효성분으로 함유하는 피부미백 개선용 조성물.
- 삭제
- 제 1항에 있어서, 상기 레몬밤 추출물은 알코올 용매추출을 이용하여 추출된 것을 특징으로 하는 피부미백 개선용 조성물.
- 제 1항에 있어서, 상기 레몬밤 추출물은 활성산소종을 제거시킴으로서 항산화 활성을 갖는 것을 특징으로 하는 피부미백 개선용 조성물.
- 제 1항에 있어서, 상기 레몬밤 추출물은 멜라닌의 합성을 저해시킴으로서 피부미백 효과를 갖는 것을 특징으로 하는 피부미백 개선용 조성물.
- 제 1항, 제 3항 및 제 4항 중 어느 한 항에 따른 조성물을 유효성분으로 함유하는 피부미백용 화장료 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100008531A KR101282335B1 (ko) | 2010-01-29 | 2010-01-29 | 레몬밤 추출물을 유효성분으로 함유하는 피부미백 개선용 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100008531A KR101282335B1 (ko) | 2010-01-29 | 2010-01-29 | 레몬밤 추출물을 유효성분으로 함유하는 피부미백 개선용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110088832A KR20110088832A (ko) | 2011-08-04 |
KR101282335B1 true KR101282335B1 (ko) | 2013-07-05 |
Family
ID=44927223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100008531A Expired - Fee Related KR101282335B1 (ko) | 2010-01-29 | 2010-01-29 | 레몬밤 추출물을 유효성분으로 함유하는 피부미백 개선용 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101282335B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102164692B1 (ko) * | 2020-01-31 | 2020-10-12 | 박장호 | 레몬밤 추출물을 포함하는 피부 미백 화장품 및 이의 제조 방법 |
KR20240020035A (ko) | 2022-08-05 | 2024-02-14 | 김수현 | 레몬밤 추출물을 유효성분으로 함유하는 아토피성 피부염 예방 및 개선효과를 갖는 조성물 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101506912B1 (ko) * | 2013-05-24 | 2015-03-31 | 주식회사 한국화장품제조 | 모과, 레몬밤 또는 오렌지블러썸 추출물을 함유하는 모공 수축 및 항산화용 화장료 조성물 |
KR102014312B1 (ko) | 2017-11-30 | 2019-08-26 | 동의대학교 산학협력단 | 참까막살 추출물을 유효성분으로 포함하는 피부 미백용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06199647A (ja) * | 1992-12-28 | 1994-07-19 | Noevir Co Ltd | 美白化粧料 |
JPH09241149A (ja) * | 1996-03-06 | 1997-09-16 | Noevir Co Ltd | 皮膚外用剤 |
KR20040087777A (ko) * | 2003-04-09 | 2004-10-15 | 애경산업(주) | 식물 추출물을 함유한 피부 미백 화장료 |
KR20070089327A (ko) * | 2006-02-28 | 2007-08-31 | (주)아모레퍼시픽 | 피부 미백용 화장료 조성물 |
-
2010
- 2010-01-29 KR KR1020100008531A patent/KR101282335B1/ko not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06199647A (ja) * | 1992-12-28 | 1994-07-19 | Noevir Co Ltd | 美白化粧料 |
JPH09241149A (ja) * | 1996-03-06 | 1997-09-16 | Noevir Co Ltd | 皮膚外用剤 |
KR20040087777A (ko) * | 2003-04-09 | 2004-10-15 | 애경산업(주) | 식물 추출물을 함유한 피부 미백 화장료 |
KR20070089327A (ko) * | 2006-02-28 | 2007-08-31 | (주)아모레퍼시픽 | 피부 미백용 화장료 조성물 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102164692B1 (ko) * | 2020-01-31 | 2020-10-12 | 박장호 | 레몬밤 추출물을 포함하는 피부 미백 화장품 및 이의 제조 방법 |
KR20240020035A (ko) | 2022-08-05 | 2024-02-14 | 김수현 | 레몬밤 추출물을 유효성분으로 함유하는 아토피성 피부염 예방 및 개선효과를 갖는 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20110088832A (ko) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lim et al. | Antioxidant properties of Phyllanthus amarus extracts as affected by different drying methods | |
Rangkadilok et al. | Evaluation of free radical scavenging and antityrosinase activities of standardized longan fruit extract | |
JP7076534B2 (ja) | 鉄皮石斛(デンドロビウム・カンディダム)花の抽出物を含む化粧料組成物 | |
Noh et al. | Antioxidant effects of the chestnut (Castanea crenata) inner shell extract in t-BHP-treated HepG2 cells, and CCl4-and high-fat diet-treated mice | |
Bazylko et al. | Inhibition of ROS production, photoprotection, and total phenolic, flavonoids and ascorbic acid content of fresh herb juice and extracts from the leaves and flowers of Tropaeolum majus | |
Palanisamy et al. | Standardized extract of Syzygium aqueum: a safe cosmetic ingredient | |
JP2009051790A (ja) | 抗酸化剤、抗老化剤、抗炎症剤、育毛剤、抗肥満剤、及び美白剤、並びに化粧料及び美容用飲食品 | |
KR20100111066A (ko) | 피부 미백용 조성물 | |
KR102158780B1 (ko) | 천연소재 추출물을 포함하는 피부 개선용 조성물 | |
JP5464730B2 (ja) | 美白剤、抗老化剤、プロフィラグリンmRNA発現上昇促進剤、育毛剤及び毛乳頭細胞増殖促進剤 | |
KR101282335B1 (ko) | 레몬밤 추출물을 유효성분으로 함유하는 피부미백 개선용 조성물 | |
Otieno et al. | Optimizing process of brewing onion peel tea using a response surface methodology | |
WO2016110276A1 (zh) | 含有黄柏酮的局部组合物及用其美白皮肤的方法 | |
KR101541520B1 (ko) | 항산화 및 항노화 활성을 갖는 황칠나무, 산수유 및 구기자 혼합 추출물의 제조방법 및 상기 추출물을 유효성분으로 함유하는 화장료 조성물 | |
JP5627585B2 (ja) | カナクギノキ由来抽出物、分画物または、化合物を含有する皮膚美白用組成物 | |
JP6143167B2 (ja) | 小眼球症関連転写因子抑制剤、メラニン産生抑制剤、化粧品組成物及び抗ガン剤 | |
JP5566733B2 (ja) | エンドセリン−1mRNA発現、幹細胞増殖因子(SCF)mRNA発現抑制剤、塩基性線維芽細胞増殖因子(bFGF)mRNA発現抑制剤、グルタチオン産生促進剤、及びフィラグリン産生促進剤 | |
Junlatat et al. | Antioxidative and melanin production inhibitory effects of Syzygium cumini extracts | |
JP2012162487A (ja) | 美白剤、抗老化剤及び皮膚化粧料 | |
KR101686521B1 (ko) | 피부 미용 개선용 조성물 | |
Boonpisuttinant et al. | Assessment of in vitro anti-skin ageing activities of Giant Indian Gooseberry (Phyllanthus indofischeri Bennet) extracts for dermatological health and aesthetic applications | |
KR20130001027A (ko) | 산초나무 추출물을 포함하는 미백용 화장료 조성물 및 그 제조방법 | |
KR20130001028A (ko) | 초피나무 추출물을 포함하는 미백용 화장료 조성물 및 그 제조방법 | |
JP5942185B2 (ja) | メラニン抑制及びmitf抑制作用を有する美白用組成物及び抗ガン剤 | |
JP5566597B2 (ja) | I型コラーゲン産生促進剤、アデノシン三リン酸産生促進剤、フィラグリン産生促進剤、メラニン産生抑制剤、塩基性線維芽細胞増殖因子(bFGF)mRNA発現抑制剤、及び肌の透明感向上剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100129 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120327 Patent event code: PE09021S01D |
|
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20121030 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130531 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130628 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20130701 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20160628 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20160628 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20170628 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180621 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20180621 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190627 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20190627 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20200629 Start annual number: 8 End annual number: 8 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20220409 |